Eculizumab for congenital atypical hemolytic-uremic syndrome.
Gruppo
Ralph A
RA
Rother
Russell P
RP
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5 / Q000037:antagonists & inhibitors*; D006463:Hemolytic-Uremic Syndrome / Q000151:congenital* / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; D007155:Immunologic Factors; C481642:eculizumab